Modular transdermal delivery system and associated methods of manufacture and use

A method for transdermally administering a pharmacologically active agent to a subject, the method comprising:

• (a) applying a separable, modular transdermal drug delivery system containing a pharmaceutical formulation comprising a first effective amount of the active agent to the skin of the subject and allowing the delivery system to remain affixed to the skin and deliver a total intended dose of the active agent to the subject throughout a first drug delivery period, wherein the transdermal drug delivery system is comprised of an upper module and a lower module that adheres to the skin and contains a porous drug reservoir that houses the pharmaceutical formulation, and, after completion of the drug delivery period:
• (b) separating the upper module from the porous drug reservoir layer-containing lower module;
• (c) refilling the porous drug reservoir with the pharmaceutical formulation;
• and
• (d) recombining the lower module with the upper module to deliver the total intended dose of the active agent to the subject throughout a second drug delivery period.

A method for transdermally administering a pharmacologically active agent to a subject, the method comprising:

• (a) applying a separable, modular transdermal drug delivery system containing a pharmaceutical formulation comprising a first effective amount of the active agent to the skin of the subject and allowing the delivery system to remain affixed to the skin and deliver a first total intended dose of the active agent to the subject throughout a first drug delivery period, wherein the transdermal drug delivery system is comprised of an upper module and a lower module that adheres to the skin and contains a porous drug reservoir that houses the pharmaceutical formulation, and, after completion of the drug delivery period:
• (b) separating the upper module from the porous drug reservoir layer-containing lower module;
• (c) refilling the porous drug reservoir with a second pharmaceutical formulation comprising a second effective amount of the active agent different from the first effective amount;
• and
• (d) recombining the lower module with the upper module to deliver a second total intended dose of the active agent to the subject throughout a second drug delivery time period, wherein the second total intended dose is different from the first total intended dose.

A method for transdermally administering a pharmacologically active agent to a subject, comprising:

• (a) applying a separable, modular transdermal drug delivery system containing a pharmaceutical formulation comprising a first effective amount of the active agent to the skin of the subject and allowing the delivery system to remain affixed to the skin and deliver a total intended dose of the active agent to the subject throughout a first drug delivery period, wherein the transdermal drug delivery system is comprised of an upper module and a lower module that adheres to the skin and contains a porous drug reservoir that houses the pharmaceutical formulation, and, after completion of the drug delivery period:
• (b) separating the upper module from the porous drug reservoir layer-containing lower module;
• (c) refilling the porous drug reservoir with a second pharmaceutical formulation comprising an effective amount of a second pharmacologically active agent different from the first active agent;
• and
• (d) recombining the lower module with the upper module to deliver a total intended dose of the second active agent to the subject throughout a second drug delivery time period.

A method for transdermally administering a pharmacologically active agent to a subject, comprising:

• (a) applying a separable, modular transdermal drug delivery system containing a pharmaceutical formulation comprising a first effective amount of the active agent to the skin of the subject and allowing the delivery system to remain affixed to the skin and deliver a total intended dose of the active agent to the subject throughout a first drug delivery period, wherein the transdermal drug delivery system is comprised of an upper module and a lower module that adheres to the skin and contains a porous drug reservoir that houses the pharmaceutical formulation, and, after completion of the drug delivery period:
• (b) separating the upper module from the porous drug reservoir layer-containing lower module;
• (c) refilling the drug delivery system with a second pharmaceutical formulation comprising the first active agent and at least one additional active agent;
• (e) recombining the lower module with the upper module to deliver a total intended dose of both the first active agent and the at least one additional active agent to the subject throughout a second drug delivery time period.

A method for transdermally administering a cannabinoid analgesic agent to a subject, the method comprising:

• (a) applying a separable, modular transdermal drug delivery system containing a pharmaceutical formulation comprising a first effective amount of the cannabinoid analgesic agent to the skin of the subject and allowing the delivery system to remain affixed to the skin to deliver a total intended dose of the cannabinoid analgesic agent to the subject throughout a first drug delivery time period;
• (b) separating the upper module of the delivery system from the porous drug reservoir layer-containing lower module, and then carrying out a further step selected from:
• (c) refilling the porous drug reservoir with the pharmaceutical formulation and recombining the lower module with the upper module to re-form the drug delivery system and deliver the total intended dose of the cannabinoid analgesic agent to the subject throughout a second drug delivery time period;
• (d) refilling the porous drug reservoir with a pharmaceutical formulation comprising a different effective amount of the cannabinoid analgesic agent, and combining the lower module with the upper module to form a dose-modified transdermal drug delivery system and deliver a different total intended dose of the cannabinoid analgesic agent to the subject throughout a second drug delivery time period;
• and
• (e) refilling the porous drug reservoir with a pharmaceutical formulation comprising an effective amount of the cannabinoid analgesic agent and at least one different active agent, and combining the lower module with the upper module to deliver the cannabinoid analgesic agent and the at least one additional active agent to the subject throughout a second drug delivery time period,
• wherein step (b) and the further step selected from (c), (d), and (e) are performed by a post-manufacture medical practitioner or by the subject.